论文部分内容阅读
目的:观察“人参二苓汤”联合厄洛替尼和单独使用厄洛替尼靶向治疗在治疗晚期非小细胞肺癌(NLCLC)的疗效和不良反应。方法:收集2007年1月—2011年10月晚期非小细胞肺癌(NLCLC)38例,随机分成治疗组和对照组,对照组予以厄洛替尼150 mg每日口服,直到疾病进展或死亡,治疗组在使用厄洛替尼治疗同时加服“人参二苓汤”。结果:治疗组和对照组在治疗晚期非小细胞肺癌(NLCLC)疗效相似(P>0.05),但在不良反应方面,治疗组在毒副反应:如皮疹、腹泻、乏力、食欲减退方面明显低于对照组(P<0.05)。结论:“人参二苓汤”联合厄洛替尼在治疗晚期非小细胞肺癌(NSCLC)确有增效解毒功效,值得在临床上推广应用。
Objective: To observe the curative effect and side effects of “Ginseng Er Ling Decoction” combined with erlotinib and erlotinib alone in the treatment of advanced non-small cell lung cancer (NLCLC). Methods: Thirty-eight patients with advanced non-small cell lung cancer (NLCLC) from January 2007 to October 2011 were randomly divided into treatment group and control group. The control group was given erlotinib 150 mg orally daily until the disease progressed or died. Treatment group in the use of erlotinib treatment plus service “ginseng Erling Tang.” Results: The treatment group and the control group had similar efficacy in the treatment of advanced non-small cell lung cancer (NLCLC) (P> 0.05), but in adverse reactions, the treatment group was significantly lower in toxicities such as rash, diarrhea, fatigue and loss of appetite In the control group (P <0.05). Conclusion: “Ginseng Er Ling Tang” combined with erlotinib in the treatment of advanced non-small cell lung cancer (NSCLC) does have synergistic detoxification efficacy, it is worth in the clinical application.